Skip to main content
. 2022 Oct 5;12:977462. doi: 10.3389/fonc.2022.977462

Table 5.

Efficacy assessment for PVTT.

TACE-125I group TACE-S group χ 2 P value
CR 1 (3.13%) 0 (0.0%)
PR 13 (40.635%) 6 (21.43%)
SD 12 (37.50%) 9 (32.14%)
PD 6 (18.75%) 13 (46.43%)
DCR 81.25% 53.57% 5.287 0.021

Unless otherwise indicated, data are numbers of patients.

CR, complete response; DCR, disease control rate; PD, progressive disease; PR, partial response; PVTT, portal vein tumor thrombosis; SD, stable disease; TACE, transarterial chemoembolisation.